Media Articles Related to Dalmane (Flurazepam)
New guideline provides clinical recommendations for specific insomnia drugs
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2017.02.16]
DA new clinical practice guideline is the first from the American Academy of Sleep Medicine to provide comprehensive, evidence-based analyses of individual agents commonly used in the treatment of...
Insomnia increases asthma risk in adults
Source: Respiratory / Asthma News From Medical News Today [2017.02.02]
A new study suggests people who experience insomnia symptoms are at a higher risk of developing asthma in adulthood compared with insomnia-free adults.
Insomnia May Increase Adult Asthma Risk (CME/CE)
Source: MedPage Today Allergy & Immunology [2017.02.02]
(MedPage Today) -- New diagnoses seen three times as often in Norwegians with sleep trouble
Sleep Disorders: Insomnia, Sleep Apnea, and More
Source: MedicineNet Jet Lag Specialty [2016.08.22]
Title: Sleep Disorders: Insomnia, Sleep Apnea, and More
Created: 7/23/2010 2:39:00 PM
Last Editorial Review: 8/22/2016 12:00:00 AM
Sleep Better, Conquer Insomnia
Source: MedicineNet zolpidem Specialty [2016.06.24]
Title: Sleep Better, Conquer Insomnia
Created: 12/10/2008 12:00:00 AM
Last Editorial Review: 6/24/2016 12:00:00 AM
Published Studies Related to Dalmane (Flurazepam)
A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers. [2006.06]
Short-acting hypnotic drugs, such as zolpidem, have minimal residual effects but may not provide optimal efficacy throughout the night for all insomnia patients... In conclusion, the study showed the good tolerance of zolpidem-MR in terms of residual neuropsychological effects as well as a beneficial effect on sleep quality in young healthy adults.
Effects of flurazepam and zolpidem on the perception of sleep in insomniacs. [1995.02]
We have shown previously that the benzodiazepine hypnotic triazolam alters the perception of being awake or asleep in insomniacs, making it more likely that they will report having been asleep when awakened by an electronic tone at various times of the night... These findings suggest that drug-induced alterations in the perception of being awake or asleep are not unique to benzodiazepines, but occur with the nonbenzodiazepine zolpidem as well.
Effects of estazolam and flurazepam on cardiopulmonary function in patients with chronic obstructive pulmonary disease. [1992.03]
Benzodiazepine drugs have been shown to suppress respiratory function in patients with chronic obstructive pulmonary disease (COPD). We designed a placebo-controlled crossover study to compare the effects of a new benzodiazepine, estazolam ('ProSom'), with those of flurazepam ('Dalmane') on cardiopulmonary function in COPD patients...
Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the Multiple Sleep Latency Test. [1991.09]
Daytime residual drowsiness and psychomotor performance were assessed for two long half-life benzodiazepines, quazepam and flurazepam, in two randomized, parallel, and double-blind studies in insomniacs... Thus, quazepam 15 mg produces less daytime somnolence and fewer psychomotor performance decrements than does flurazepam.
Hypnotic efficacy of estazolam compared with flurazepam in outpatients with insomnia. [1991.08]
Estazolam is a new benzodiazepine hypnotic agent with an intermediate half-life of 12 to 15 hours... Estazolam 1 mg is also effective in the treatment of outpatients with insomnia, but to a lesser degree.
Clinical Trials Related to Dalmane (Flurazepam)
Study to Evaluate the Effect of 2 Dosage Strengths of E2006 on a Multiple Sleep Latency Test in Subjects With Insomnia Disorder [Completed]
This is a single-dose, randomized, placebo-controlled, 3-way crossover study of 2 dosage
strengths of E2006 (5 mg and 10 mg) in subjects with insomnia disorder.
Pharmacovigilance in Gerontopsychiatric Patients [Recruiting]
The purpose of this multicenter-study is to investigate safety of psychopharmacological
treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly
people are at higher risk for developing side effects under pharmacological treatment due to
an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore
gerontopsychiatric patients can often not articulate their symptoms clearly, for example due
to pronounced cognitive impairment.
The aim of the study is to gain valid data of possible adverse drug reaction rates, their
potential risk factors and outcome, as well as medical prescription practises.
To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the
five participating study sites.
At Baseline demographic data, previous and present disorders, use of drugs, previous and
present medication, quality of life, cognitive function, physical examination results,
laboratory results and ECG will be assessed.
Afterwards patients are visited weekly and screened for possible adverse drug reactions. All
adverse drug reactions will be coded in the MedDRA-system.
In case of a possible serious adverse drug reaction serum levels of all psychotropic
substances applicated will be assessed. Drug combinations will be analysed using an
established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible
adverse drug reactions are documented continually.
2 weeks after discharge from the ward, patients will be contacted by phone to assess
Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo [Completed]
Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons [Completed]
Benzodiazepines (BZDs) have been reported to cause negative impacts on motor as well as
cognitive functions, which in turn could result in lethal incidents including falls
especially in the elderly. This notwithstanding, few trials have evaluated a feasibility and
benefits of discontinuing BZD-derivative hypnotics in a systematic manner in this frail
population. In this 8-week open-label study, we examined changes in motor and cognitive
functions following the discontinuation of BZD hypnotics in older persons.
OBJECTIVES & HYPOTHESES
1. Primary Objective The primary objective is to examine the feasibility of discontinuing
BZD-derivative hypnotics in older people.
2. Secondary Objectives
1. One of the secondary objectives is to examine the magnitude of discontinuing
BZD-derivative hypnotics in the stability of body.
2. Another secondary objective is to examine the magnitude of discontinuing
BZD-derivative hypnotics in cognitive function.
1. More than 80% of the participants will complete and tolerate all the study procedures.
2a. Participants will show an improvement in the stability of body. 2b. Participants will
show an improvement in the cognitive function globally as well as specifically in attention.